Appeals Court Blocks Mail-Order Abortion Pills, Alito Grants Temporary Stay

Patients and providers across the country now navigate fresh uncertainty over access to medication abortion after a federal appeals court reinstated requirements for in-person dispensing of mifepristone. The decision, issued Friday by a unanimous panel of the 5th U.S. Circuit Court of Appeals, halted a Biden-era FDA policy that had allowed prescriptions via telehealth and delivery by mail since 2021. Justice Samuel Alito paused that ruling Monday evening, preserving current access at least until May 12, 2026, while the Supreme Court considers further arguments.

At the center of the dispute lies a contradiction that has persisted since the 2022 Dobbs decision: federal regulators expanded mifepristone's availability citing safety data, yet multiple states and now courts question whether those changes followed proper procedure. Louisiana led the current lawsuit, arguing the FDA's removal of the in-person visit requirement in 2016, 2021 and 2023 violated the Administrative Procedure Act by relying on insufficient evidence of risks including off-label use and complications. The 5th Circuit agreed enough to order reinstatement of the original 2000 approval terms pending full review of the merits, a step the court said would prevent irreparable harm to states enforcing their own abortion limits. The Supreme Court had previously ruled in June 2024 that individual anti-abortion doctors lacked standing to challenge those same FDA actions.

The immediate result is operational whiplash. Some telehealth providers and pharmacies paused mifepristone prescriptions after the circuit ruling, according to the National Abortion Federation. Others, including Planned Parenthood of Greater New York, shifted temporarily to misoprostol alone. The FDA has not issued public guidance on handling existing prescriptions or what new rules would look like if the stay lifts. Danco Laboratories, which manufactures mifepristone, told the Supreme Court the absence of clarity itself creates disruption. The Trump administration has asked courts to pause litigation while the FDA completes a fresh safety review; that position drew criticism from both anti-abortion groups who want faster reversal of Biden policies and abortion-rights organizations who call the legal back-and-forth chaotic for time-sensitive care.

The litigation intersects with stricter state regimes. In Florida, where a six-week ban took effect in 2024, the Guttmacher Institute reported abortions provided in-state fell from roughly 88,000 in 2023 to 65,800 in 2025. Florida residents traveling out of state for care nearly tripled from 2,800 to 8,200 in the first year after the ban, with preliminary figures showing continued increases. Funds such as the Chicago Abortion Fund reported assisting 360 Floridians in the year after the ban, up 267 percent, at a cost exceeding $180,000. These numbers could not be independently verified in full by state health department figures, which reported 84,052 abortions in 2023. Nationally, Guttmacher data indicate total abortions have remained near one million annually despite wide state variation.

Legal observers note the current case differs from the 2024 Supreme Court standing decision because it is brought by state attorneys general seeking to protect their enforcement interests rather than individual physicians. No ruling has yet issued on Louisiana's core claim that the FDA acted arbitrarily. Parties have until Thursday to file additional briefs with the Supreme Court. The one-week stay expires next Monday. How pharmacies, clinicians and patients would adapt to a permanent in-person requirement remains unclear, particularly in the 14 states where telehealth had become a primary route for medication abortion that now accounts for six in ten procedures.